相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Qinghai Zeng et al.
CLINICAL CANCER RESEARCH (2018)
FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells
Sevil Oskay Halacli
CELL BIOLOGY INTERNATIONAL (2017)
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia
L. M. Saleh et al.
LEUKEMIA (2017)
MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness
Swati Dhar et al.
FEBS LETTERS (2017)
PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells
Cecile Naudin et al.
BLOOD (2017)
Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance
Yiwen Bu et al.
CANCER LETTERS (2016)
miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer
Lorenza Pasqualini et al.
MOLECULAR ENDOCRINOLOGY (2015)
The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema
Wen Lu et al.
NATURE IMMUNOLOGY (2015)
Altered radiation responses of breast cancer cells resistant to hormonal therapy
Lidiya Luzhna et al.
ONCOTARGET (2015)
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA
Erin L. Hayes et al.
BREAST CANCER RESEARCH (2015)
A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis
Ling-Min Kong et al.
CANCER RESEARCH (2014)
miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1
Hafiz M. Ahmad et al.
FEBS JOURNAL (2014)
MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling
Su Jung Song et al.
CELL (2013)
The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation
Su Jung Song et al.
CELL STEM CELL (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Forkhead box proteins: tuning forks for transcriptional harmony
Eric W. -F. Lam et al.
NATURE REVIEWS CANCER (2013)
NFκB signaling is important for growth of antiestrogen resistant breast cancer cells
Christina W. Yde et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients
Mathias Warm et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer
Francesco Boccardo et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2
James W. Antoon et al.
CANCER BIOLOGY & THERAPY (2011)
Tumor Suppressor miR-22 Determines p53-Dependent Cellular Fate through Post-transcriptional Regulation of p21
Naoto Tsuchiya et al.
CANCER RESEARCH (2011)
Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells
Jian Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
X. Rao et al.
ONCOGENE (2011)
FOXP1, an Estrogen-Inducible Transcription Factor, Modulates Cell Proliferation in Breast Cancer Cells and 5-Year Recurrence-Free Survival of Patients with Tamoxifen-Treated Breast Cancer
Takashi Shigekawa et al.
Hormones & Cancer (2011)
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
J. Zhang et al.
BRITISH JOURNAL OF CANCER (2010)
An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples
Jianhua Xiong et al.
FEBS JOURNAL (2010)
Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα
E. C. Merkhofer et al.
ONCOGENE (2010)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Most mammalian mRNAs are conserved targets of microRNAs
Robin C. Friedman et al.
GENOME RESEARCH (2009)
Advances in microRNAs: implications for immunity and inflammatory diseases
E. Sonkoly et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
D. Mottet et al.
ONCOGENE (2009)
CDK inhibitors: Cell cycle regulators and beyond
Arnaud Besson et al.
DEVELOPMENTAL CELL (2008)
Cooperative regulation in development by SMRT and FOXP1
Kristen Jepsen et al.
GENES & DEVELOPMENT (2008)
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Tyler E. Miller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Andrew J. Wilson et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
Vanessa Duong et al.
MOLECULAR CANCER RESEARCH (2008)
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
Witold Filipowicz et al.
NATURE REVIEWS GENETICS (2008)
Estrogen receptor pathway: Resistance to endocrine therapy and new therapeutic approaches
Beverly Moy et al.
CLINICAL CANCER RESEARCH (2006)
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1
Y Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Pure oestrogen antagonists for the treatment of advanced breast cancer
Anthony Howell
ENDOCRINE-RELATED CANCER (2006)
Achieving stability of lipopolysaccharide-induced NF-κB activation
MW Covert et al.
SCIENCE (2005)
c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells
S Mukherjee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Endocrine therapy - current benefits and limitations
RI Nicholson et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Life following aromatase inhibitors - where now for endocrine sequencing?
SR Johnston et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib ('Iressa', ZD1839)
S Hiscox et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Double-blind, Randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
CK Osborne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
S Cariou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
